The same strain may be regulated differently depending on dosage form, intended population, route of administration, claims, food history, and whether the product is live, non-viable, conventional food, supplement, NHP, or therapeutic product.
Without early alignment between regulatory strategy, claims, and evidence, companies face delays, reclassification risks, and lost market opportunities.
Key challenges include:
These challenges make regulatory strategy a critical component of product development—not an afterthought.
Europe
Advanced / Therapeutic Pathways
Probiotic claims are among the most scrutinized in the industry. Misalignment between claims and evidence is one of the leading causes of regulatory delays and compliance issues.
Our integrated approach ensures your probiotic product is not only compliant—but positioned for long-term commercial success.
It depends on the market and intended use. In the U.S., many probiotic supplements can be marketed without pre-approval, while in Canada, probiotics are typically regulated as Natural Health Products (NHPs) and require licensing. In the EU, requirements vary depending on the product classification and whether the strain is considered novel.
The primary driver is intended use and claims. Products making general wellness or structure/function claims may be regulated as foods or supplements, while products claiming to treat or prevent disease are typically regulated as drugs and require clinical trials and regulatory approval.
A New Dietary Ingredient Notification (NDIN) may be required when a probiotic strain or dietary ingredient is considered a New Dietary Ingredient under DSHEA and no exemption applies, such as prior marketing before October 15, 1994 or presence in the food supply as an article used for food in a chemically unaltered form. If required, the notification must generally be submitted to FDA at least 75 days before marketing.
In Canada, many probiotic products are regulated as Natural Health Products when sold in NHP dosage forms and positioned for NHP uses. Food-format probiotic products may require separate classification analysis under the food/NHP interface, and non-viable or postbiotic-style ingredients may not fit the probiotic monograph pathway.
The European Food Safety Authority (EFSA) has strict requirements for health claims. Most probiotic-related claims have not been approved due to insufficient strain-specific clinical evidence. As a result, even the term “probiotic” may be restricted in some EU countries.
Not always from a legal standpoint, but in practice, clinical evidence is often essential to support claims, differentiate products, and meet expectations from regulators, retailers, and consumers. Probiotic effects are strain-specific and typically require human data for substantiation.
The biggest risk is misalignment between claims, evidence, and classification. Even small changes in wording can shift a product into a different regulatory category, leading to delays, additional requirements, or enforcement action.
Probiotics are living organisms, which introduces additional considerations such as strain identification, viability over shelf life, and variability in human response. These factors increase scrutiny around safety, efficacy, and labeling compared to traditional ingredients.
No—regulatory frameworks vary significantly across regions. A product compliant in the U.S. may not be acceptable in Canada or the EU without modifications to claims, labeling, or supporting evidence. A global strategy must be adapted market by market.
Not necessarily. Postbiotics, heat-killed microorganisms, and other non-viable microbial preparations may fall outside traditional probiotic pathways and may require separate classification, safety, claims, and evidence review.